ARDS:NSD-Aridis Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.21

Change

+0.01 (+0.45)%

Market Cap

USD 0.04B

Volume

0.08M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

ARDS Stock Forecast & Price:
Based on the Aridis Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Aridis Pharmaceuticals Inc is not available over the next 12 months. Aridis Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aridis Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 8 negative signals. At the last closing, Aridis Pharmaceuticals Inc’s stock price was USD 2.21. Aridis Pharmaceuticals Inc’s stock price has changed by +8.87% over the past week, +79.67% over the past month and -47.26% over the last year.

About Aridis Pharmaceuticals Inc (ARDS:NSD)

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of ...Read More

Company Website : https://www.aridispharma.com

Address : 983 University Avenue, Los Gatos, CA, United States, 95032

Employees : 34

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.13

52 Week High : 4.34

Short Ratio : 2.10

52 Week Low : 0.88

Shorted Shares : 123,807

200 Day Moving Average : 1.83

Shorted Shares Previous Month : 96,730

50 Day Moving Average : 1.39

Shares Held By Insiders : 32.77%

Short Percentage : 0.60%

Shares Held by Institutions : 10.06%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

 USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

 USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

 USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

 USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

 USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

 USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

 USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

 USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

 USD20.61B N/A -20.22

ETFs Containing ARDS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.15% 78% C+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.15% 78% C+ 63% D
Trailing 12 Months  
Capital Gain -47.38% 57% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.38% 57% F 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.09% 20% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.09% 20% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 33.51% 83% B 48% F
Risk Adjusted Return -71.89% 16% F 8% F
Market Capitalization 0.04B 22% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.83 62% D- 89% B+
Price/Book Ratio 5.40 19% F 17% F
Price / Cash Flow Ratio -1,697,625.11 100% A+ 100% A+
EV/EBITDA -0.85 49% F 63% D
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 543.06% 99% A+ 99% A+
Return on Assets -130.59% 2% F 1% F
Debt to Equity Ratio -37.43% 93% A 93% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.10 65% D 62% D-
Short Percent 0.60% 87% B+ 80% B-
Beta 1.13 57% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector